Ranbaxy’s right to sell a generic version of Pfizer’s cholesterol-lowering drug, Lipitor, in the United States for six months has been challenged in a court. This is considered a $600-million (Rs 2,700 crore) opportunity for the company. US-based Mylan Laboratories has sued the US Food and Drug Administration (FDA) for giving this opportunity to Ranbaxy. The company wants that all generic players including Mylan be allowed to enter the market as soon as the patent protection on Lipitor ends in November.
Ranbaxy holds the right as it was the first to challenge a later date patent on the drug and apply for supply of a generic, low-cost version as soon as the basic patent expires. According to Mylan, Ranbaxy was not eligible for marketing exclusivity because of “false and unreliable data” from its manufacturing site in Paonta Sahib, India, where Lipitor’s copies would be produced. The facility was earlier under the FDA scanner for falsifying data.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: